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ABSTRACT
Human papilloma virus (HPV)-associated head and neck squamous cell carcinoma 
(HNSCC) has a better prognosis than it’s HPV negative (HPV(−)) counterpart. This may 
be due to the higher numbers of tumor-infiltrating lymphocytes (TILs) in HPV positive 
(HPV(+)) tumors. RNA-Sequencing (RNA-Seq) was used to evaluate whether the 
differences in clinical behaviour simply reflect a numerical difference in TILs or whether 
there is a fundamental behavioural difference between TILs in these two settings. Thirty-
nine HNSCC tumors were scored for TIL density by immunohistochemistry. After the 
removal of 16 TILlow tumors, RNA-Seq analysis was performed on 23 TILhigh/med tumors 
(HPV(+) n=10 and HPV(−) n=13). Using EdgeR, differentially expressed genes (DEG) 
were identified. Immune subset analysis was performed using Functional Analysis of 
Individual RNA-Seq/ Microarray Expression (FAIME) and immune gene RNA transcript 
count analysis. In total, 1,634 DEGs were identified, with a dominant immune signature 
observed in HPV(+) tumors. After normalizing the expression profiles to account for 
differences in B- and T-cell number, 437 significantly DEGs remained. A B-cell associated 
signature distinguished HPV(+) from HPV(−) tumors, and included the DEGs CD200, 
GGA2, ADAM28, STAG3, SPIB, VCAM1, BCL2 and ICOSLG; the immune signal relative 
to T-cells was qualitatively similar between TILs of both tumor cohorts. Our findings 
were validated and confirmed in two independent cohorts using TCGA data and tumor-
infiltrating B-cells from additional HPV(+) HNSCC patients. A B-cell associated signal 
segregated tumors relative to HPV status. Our data suggests that the role of B-cells in 
the adaptive immune response to HPV(+) HNSCC requires re-assessment.
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) 
accounts for 6% of all cancers, with ~650,000 new cases 
reported and 350,000 HNSCC-related deaths per year 
worldwide [1, 2]. Historically, the risk factors for HNSCC 
have been smoking and alcohol [3]. However, changes 
in social behaviour have led to an increase in human 
papilloma virus (HPV)-associated HNSCC [4]. The 
incidence of HPV-associated HNSCC is approximately 
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30% [5–7], of which the majority are caused by HPV16 
within the anatomical location oropharynx, which includes 
the base of tongue and tonsil [6]. HPV positive (HPV(+)) 
patients have a significantly better prognosis than HPV 
negative (HPV(−)) patients, with the 3- and 5-year 
survival at 84% and 62% for HPV(+) patients compared 
to 57% and 26% for HPV(−) patients, respectively [8].
A high number of tumor-infiltrating lymphocytes 
(TILs) is linked to good prognosis in many solid tumors, 
including HPV(+) HNSCC [9]. More recent analyses of 
The Cancer Genome Atlas (TCGA) data demonstrate 
that the effect is mediated by CD8+ GZMA+ PRF1+ 
T-cells [10, 11]. In HPV(+) disease, the persistent viral 
oncoproteins E6 and E7 cause the malignant phenotype, 
while the immunological visibility of these two proteins 
contributes to the infiltration of the tumor by T-cells [12]. 
By contrast, HPV(−) tumors are considered a separate 
disease entity and are driven by heterogeneous genetic 
events [11, 13]. Differential gene expression profiling 
comparing HPV(+) and HPV(−) tumors using microarray, 
RNA-Sequencing (RNA-Seq) and RT-PCR have led to 
an improved understanding of the events associated with 
cellular transformation and oncogenesis [14–17]. Thurlow 
et al. have used spectral clustering and gene ontology 
(GO) analysis to identify discrete gene expression patterns 
that linked to patient outcome, which involved the genes 
of adaptive and innate immunity [17]. However, the 
underlying biology of TILs has not been addressed despite 
their clear link to survival [7, 11, 14–16, 18, 19].
Our aim was to evaluate whether transcriptome analysis 
would identify characteristics that could differentiate TILs in 
HPV(+) from those in HPV(−) tumors. We established and 
optimized sample collection from a cohort of consecutive 
patients under our care that were undergoing surgery for 
HNSCC. Tumor samples were processed according to 
controlled standard operating procedures and evaluated both 
morphologically and by immunohistochemistry (IHC) on 
the one hand, and by RNA-Seq to determine whole tumor 
transcriptomes on the other. We demonstrated that after 
correction for the number of immune cells infiltrating the 
tumors, the T-cell signature between HPV(+) and HPV(−) 
tumors was very similar. By contrast, B-cell associated genes 
emerged as differentially expressed. High expression of these 
genes proved to be a distinguishing immunological feature 
of HPV(+) HNSCC, suggesting a fundamental biological 
difference in adaptive immune responses against virally 
driven versus virus-independent tumors. We were able to 
verify our findings in a large publicly available dataset from 
TCGA (HNSC) and also by RT-qPCR of the key DEGs.
RESULTS
Prognostic effect of TIL density
We had previously demonstrated that in HPV(+) 
HNSCC TIL density correlates with outcome [7]. From 
this starting point we undertook a multi-step analysis to 
understand the features of tumor-infiltrating immune 
cells in patients with both HPV(+) and HPV(−) HNSCC 
(Figure 1).
Using the same methodology as previously [7], 
we extended our cohort (n=544) to include HPV(−) 
HNSCC. As in HPV(+) tumors, TIL status stratified for 
outcome in HPV(−) HNSCC (Figure 2). Furthermore, 
HPV(+) TILhigh/mod patients had significantly better 
survival compared to HPV(−) TILhigh/mod patients (Figure 
2, log rank p<0.001). In order to better understand this 
survival difference, we examined the transcriptome 
associated with TILs in a prospective cohort (n=39), 
patient demographics, tumor characteristics and tumor 
sampling/ processing information for the HPV(+) 
and HPV(−) patient cohorts are shown in Table 1. As 
our interest was in understanding immune cells, we 
focussed on TIL rich (TILhigh/mod) tumors and excluded 
the 16 TILlow cases from our analyses. Of the 23 TILhigh/
mod cases, 10 were HPV(+) and 13 were HPV(−). The 
clinical and histological descriptors were distributed as 
expected (Table 1); HPV(+) tumors were located in the 
oropharynx of non-smoking patients, HPV(−) tumors 
were located in the larynx (n=4), oral cavity (n=5) and 
oropharynx (n=4). The clinical classification of HPV 
status was determined by routine IHC against p16 and 
mapped appropriately to the expression of E6 and E7, as 
detected by RNA-Seq (Table 1).
Gene expression analysis of HPV(+) and HPV(−) 
tumors
Following RNA-Seq analysis, 1,634 genes were 
identified as significantly differentially expressed (q-
value <0.05) between the HPV(+) and HPV(−) tumors 
(Figure 3A and Supplementary Table S1). Of these 
genes, 894 were expressed to a greater extent and 740 to 
a lesser extent in HPV(+) compared to HPV(−) tumors. 
These gene expression differences segregated HPV(+) 
and HPV(−) tumors in all except one HPV(−) subject 
(patient 21), whose tumor clustered within the HPV(+) 
cohort (Figure 3A). On histological review, this patient 
had a basaloid SCC, which is a rare and clinically distinct 
HNSCC subform. We therefore removed this case from 
further evaluation.
Gene expression of the HPV associated genes 
CDKN2A (p16), E6 and E7 were as expected between 
HPV(+) and HPV(−) tumors (Figure 3B). We also found 
differences in the expression of genes associated with 
‘immune cell markers’ between HPV(+) and HPV(−) 
tumors (Figure 3B); expression of these genes was greater 
in HPV(+) tumors. Similarly, the expression of GZMA, 
IFNG and CDNK2A and key genes that link to T-cell 
activation and exhaustion, such as CTLA4, PD1 and 
HAVCR2 (encoding TIM3), were all increased in HPV(+) 
compared to HPV(−) tumors.
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Figure 1: Overview of experimental procedures and analysis used to evaluate TIL. Schematic representation of the multi-step 
analysis performed to understand the features of tumor-infiltrating immune cells in patients with HPV(+) and HPV(−) HNSCC.
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GO and pathway analysis
GO and pathway analysis was performed to 
understand the biological significance of the 1,634 DEGs. 
GO terms that were significantly over-represented for 
DEGs were identified using CPDB [20]; GO analysis was 
performed independently for those genes expressed to a 
greater extent and for genes expressed to a lesser extent 
in HPV(+) compared to HPV(−) tumors. Full details of 
the GO terms, including the specific genes, number and 
percentage of DEGs associated with each GO term, are 
presented in Supplementary Tables S2 and Supplementary 
S3 respectively.
Figure 2: Kaplan-Meier curves for HNSCC mortality stratified according to HPV status and TIL density. Survival of 
a retrospective cohort of HNSCC patients (n=544) with respect to HPV status and the density of immune cell infiltrate was assessed. TIL 
density predicts for outcome in both the HPV(+) and HPV(−) patients; log-rank test, p<0.001.
Oncotarget5www.impactjournals.com/oncotarget
Table 1: Clinical and histopathological information for HPV(+) and HPV(−) HNSCC patients
Variable Description HPV(+) HPV(−) p-value Test≠
(n=10) (n=13)
Gender % Male 90.00 76.92 6.04E-01 a
Age Mean 56.90 ± 8.66 63.77 ± 15.85 2.32E-01 b
Collection site Liverpool 1 0
Poole 2 6 2.81E-01 a
Southampton 7 7
Sequencing Batch 1 3 6
2 7 5 3.92E-01 a
3 0 2
RIN* Mean 8.51 ± 0.80 8.51 ± 1.01 7.56E-01 c
Smoking Non smoker 10 6
Smoker 0 4 2.56E-02 a
Heavy smoker 0 3
Alcohol Non drinker 5 3
Moderate drinker 4 9 4.02E-01 a
Heavy drinker 1 1
Tumor site Larynx 0 4
Oral 0 5 1.60E-03 a
Oropharynx 10 4
White blood cells Mean 9.47 ± 2.23 8.52 ± 1.92 2.86E-01 b
Lymphocytes Mean 1.82 ± 0.60 1.77 ± 0.81 5.76E-01 c
Staging I 0 3
II 1 0 3.48E-01 a
III 2 3
IV 7 7
TIL status High 8 4 3.61E-02 a
Medium 2 9
Pattern of invasion Cohesive 10 6 7.49E-03 a
Discohesive 0 7
Differentiation Poor 9 2
Moderate 1 9 8.85E-04 a
Well 0 2
Smooth muscle actin Low 10 9
Moderate 0 2 2.37E-01 a
High 0 2
Tumor cell % 68.00 ± 20.58 65.38 ± 21.06 7.69E-01 B
E6 expression Mean 4.57 ± 1.11 -4.36 ± 0.57 1.75E-06 C
E7 expression Mean 5.07 ± 1.30 -4.36 ± 0.57 1.75E-06 C
*RIN; RNA integrity number
≠P-values were obtained from Fisher’s exact test (a) for categorical variables. A two sample t-test (b) was performed for numerical variables with normal 
distribution (Shapiro-Wilk test, P≥0.05). A Wilcoxon rank sum test (c) was performed for numerical variables with non-normal distribution (Shapiro-Wilk 
test, P<0.05). Statistically significant p-values (<0.05) are indicated in bold.
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Figure 3: Differentially expressed genes between HPV(+) and HPV(−) tumors. A. a heatmap to illustrate the DEGs between 
HPV(+) and HPV(−) tumors; each row represents the z-score of normalized gene expression values for a given gene; each column represents 
the gene expression for a given tumor. Z-scores are calculated from the average gene expression, plus standard deviation, in all tumors for 
a given gene, this enables the relative comparison of gene expression between tumors; the scale of z-score is shown: red shading denotes 
greater gene expression, blue shading denotes lower gene expression. Hierarchical clustering of genes and tumors based on their expression 
profile is reflected in the dendrograms to the left and the top of the heatmap, respectively, and was performed by calculating distance using 
the Pearson’s correlation metric and then clustering distance using the ward linkage method*. B. the expression of key genes associated with 
HPV, immune cell markers, immune effector function and immune exhaustion/regulation are displayed for HPV(+) and HPV(−) tumors as 
box plots (min/max) with the + representing the mean. A greater expression of immune associated genes is observed in HPV(+) tumors**. 
*Unsupervised clustering of gene expression data was normalized using the TMM method followed by variance stabilizing transformation 
of the TMM normalized data. **Gene expression data from the normalized transcript counts; data was normalized using the TMM method 
followed by variance stabilizing transformation of the TMM normalized data.
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Our data revealed that those genes with greater 
expression in the HPV(+) cohort were predominantly 
associated with an immune reaction (e.g., adaptive 
immune response, GO:0002250; lymphocyte activation, 
GO:0046649; positive regulation of immune system 
process, GO:0002684; B-cell activation, GO:0042113), 
whereas those expressed to a lesser extent were associated 
with cellular processes involved in tissue development, 
(GO:0009888), keratinization (GO:0031424) and cell 
differentiation (GO:0030154). Specifically, there was 
greater expression of genes associated with the adaptive 
immune system, including T-cells (CD4+ and CD8+) and 
B-cell receptor signalling pathways, as well as NK-cell-
mediated cytotoxicity (Supplementary Table S2).
Those genes expressed to a lesser extent represented 
different biological processes, including extracellular 
matrix organisation, collagen formation, beta1 integrin 
cell surface interactions and alpha6 beta4 integrin-ligand 
interactions (Supplementary Table S3). The biological 
pathways (e.g., KEGG) over-represented for DEGs 
mirrored the results of GO analysis displaying an enriched 
number of genes linked to immunological signalling 
pathways in greater expressed genes (Supplementary 
Tables S4) and pathways linked to extracellular matrix 
organisation and collagen formation in genes expressed to 
a lesser extent (Supplementary Tables S5).
Quantification of TILs
GO and pathway analysis indicated that the 
biological processes related to the immune system and 
specifically to B and T-cells were over-represented for 
genes expressed to a greater extent in HPV(+) tumors 
(Figure 3B and Supplementary Tables S2 and S4). 
However, it was not clear whether these B- and T-cell 
immune-related terms identified by GO and pathway 
analysis were simply the result of numerical differences 
in lymphocytes between HPV(+) and HPV(−) tumors 
or the result of differences on a per cell basis in the 
transcriptional signature.
To be able to address this question we compared 
three approaches to quantifying tumor-infiltrating 
lymphocytes: IHC for CD4, CD8, CD20 and CD3 
followed by manual counting of 10 high-power fields 
(Figure 4A), gene RNA transcript levels (log2 normalised) 
for lymphocyte cell surface markers (Figure 4B) and 
computational evaluation using FAIME to measure the 
size of lymphocyte subsets in each sample (Figure 4C). 
A significant difference in cell number was observed 
between HPV(+) and HPV(−) tumors for the cell markers 
CD4, CD20 and CD3 (P ≤ 0.05) but not CD8 (ns) by IHC. 
Gene RNA transcript levels were significantly different for 
all cell markers (CD4, CD20, CD3e and CD8A) (Figure 
4B). Spearman correlation analysis between IHC and 
gene expression for the cell markers CD8 (R2=0.76), CD3 
(R2=0.52) and CD19 (R2=0.47) is shown in Supplementary 
Figure S1A, B and C respectively. FAIME analysis uses 
gene expression biomarkers (Supplementary Table S6) to 
score the size of each lymphocyte subset; this score was 
significantly different between the HPV(+) and HPV(−) 
tumors for B-cells (q-value =1.35E-03), CD4+ T-cells (q-
value =2.66E-02) and CD8+ T-cells (q-value =9.64E-03). 
FAIME scores indicated that the number of cells belonging 
to these lymphocyte subsets was higher in HPV(+) tumors 
compared to HPV(−) tumors.
Both molecular analyses demonstrated that the 
numbers of B-cells and CD4+ and CD8+ T-cells were 
higher in HPV(+) tumors compared to HPV(−) tumors, 
this was confirmed by the ‘gold standard’ assessment by 
IHC for B-cells, CD3+ T-cells and CD4+ T-cells (P ≤ 0.05). 
A significant difference was not observed by IHC for 
CD8+ T-cells, however a trend towards higher numbers in 
HPV(+) was observed (Figure 4A).
Analysis of gene expression data following 
correction for numerical differences in TILs
The global gene expression data were next 
corrected for TIL number using the gene expression 
of CD19 (pan B-cell marker, CD20 was used only for 
IHC comparison), CD4 and CD8A in each sample as a 
covariate. When correcting both HPV(+) and HPV(−) 
cohorts in this way, genes co-ordinately expressed 
in lymphocyte subsets were no longer differentially 
expressed; as a result the number of DEGs dropped 
from 1,634 to 437 (Supplementary Table S7). As 
expected, there was a large overlap in DEGs between 
the initial uncorrected and the TIL corrected data sets 
(Supplementary Figure S2). The TIL corrected dataset 
was next subject to GO and pathway analysis.
GO and pathway analysis of TIL corrected data
GO and pathway analysis was again performed 
independently for genes expressed to a greater extent 
(n=219; Supplementary Table S8) and a lesser extent 
(n=218; Supplementary Table S9) in HPV(+) compared 
to HPV(−) tumors. Consistent with the FAIME analysis, 
the vast majority of immune and lymphocyte-related 
terms were no longer over-represented in HPV(+) tumors. 
This included markers of T-cell effector function (e.g., 
IFNG, GZMB and PRF1; Figure 3B), which prior to TIL 
correction were all over-represented in the HPV(+) tumors. 
Pathway analysis also confirmed the loss of immune-related 
signalling pathways (Supplementary Table S10).
Immune GO terms that remained following correction 
for numerical differences in TIL were B-cell activation 
(GO:0042113), which included BCL2, VCAM1 and ICOSLG, 
with a greater expression in HPV(+) compared to HVP(−) 
tumors (Supplementary Table S8). The surviving non-
immune GO terms and biological pathways (Supplementary 
Table S8 and S10) over-represented in HPV(+) tumors were 
associated with cell cycle (GO:0007049), cell phase transition 
(GO:0044770) and chromosome organisation (GO:0051276).
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Figure 4: Immune cell subset analysis of HPV(+) and HPV(−) tumors. A. The distribution of CD4, CD8, CD3 and CD20-
expressing cells in HPV(+) and HPV(−) tumors as detected by IHC; cell counts are given as a mean of 10 high-power fields. B. Gene 
expression of CD4, CD8A, CD3E and CD20 of HPV(+) and HPV(−) tumors displayed as box plots (min/max) with the + representing the 
mean*. Differences in TIL density between HPV(+) and HPV(−) tumors are observed both by gene expression profiling and IHC analysis. 
C. the FAIME score of lymphocytes in HPV(+) and HPV(−) tumors; the difference in distribution of specific cell subsets based on ranked 
gene expression is shown. Asterisks in column labels indicate a significance level of two-sample t-test comparisons of FAIME scores 
between HPV(+) and HPV(−) tumors: *P <0.05 and **P <0.01). *Gene expression data from the normalized transcript counts; data was 
normalized using the TMM method followed by variance stabilizing transformation of the TMM normalized data.
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The loss of T-cell and the majority of B-cell-related 
GO terms following TIL correction of gene expression 
data indicated that gene expression differences between 
HPV(+) and HPV(−) tumors largely resulted from 
numerical differences in these cells types. To determine 
if any differences in lymphocyte gene expression between 
the HPV(+) and HPV(−) tumor cohorts were retained 
following TIL correction, the DEGs identified after 
correction were overlapped with the lymphocyte-specific 
marker genes used to determine the cell proportions in 
the FAIME analysis (CD19+ B-cell genes and CD8+ and 
CD4+ T-cell genes, Supplementary Table S6 [21–26]). The 
majority of the surviving signals were associated with the 
following B-cell associated genes: GGA2, SPIB, CD200, 
ADAM28 as well as STAG3, which was not previously 
known to be a B-cell gene. A single CD8-associated gene 
(CD8B) also survived correction (Supplementary Figure 
S3).
Validation of findings using TCGA RNA-Seq 
data
We next assessed the expression of the identified 
DEGs (n=437) including the 8 B-cell-related genes GGA2, 
SPIB, CD200, ADAM28, BCL2, VCAM1, ICOSLG and 
STAG3, in an independent HNSCC dataset from TCGA 
(TCGA HNSC HiSeqV2 2015-02-24 data source outlined 
in methods) [11].
Analysis of TCGA data allowed us to address 
whether the DEGs might be the result of anatomical 
bias: since HPV(+) tumors predominantly arise in 
specific anatomical locations (tonsil, base of tongue and 
oropharynx) these might per se contribute to DEGs. Hence 
we identified 72 cases (46 HPV(+) and 26 HPV(−)) from 
anatomically matched locations (tonsil, base of tongue and 
oropharynx). Visualisation of the 8-gene signature (GGA2, 
SPIB, CD200, ADAM28, BCL2, VCAM1, ICOSLG and 
STAG3) identified from our cases in a hierarchically 
clustered heatmap (Figure 5A) together with the 72 
TCGA cases (Figure 5B) demonstrated the clustering 
of tumors according to HPV status, with a greater gene 
expression in HPV(+) compared to HPV(−) tumors. These 
data confirmed that anatomical bias was not the reason 
for the B-cell-associated differences in gene expression. 
Unsupervised hierarchical clustering of all 437 TIL 
corrected DEGs for our own dataset and TCGA data is 
shown in Supplementary Figure S4.
Validation of RNA-seq data by RT-qPCR and 
IHC
We confirmed our findings with RT-qPCR, 
identifying the expression of the genes GGA2, SPIB, 
CD200, STAG3, ADAM28, BCL2, VCAM1 and ICOSLG 
in B-cells isolated from an independent HPV(+) HNSCC 
tumor cohort (n=6) (Figure 6). In addition to this, RT-qPCR 
of CD200 and STAG3 was carried out on the whole tumor 
RNA samples used for the RNA-Seq (n=8 HPV(+) and 
n=8 HPV(−). This showed the same trend with HPV(+) 
tumors compared to HPV(−) tumors having increased 
expression of STAG3 and CD200 (Supplementary Figure 
S5; STAG3, ***p<0.001 and CD200 nsd, p=0.116). We 
have exhausted the material meaning additional genes 
and cases could not be assessed, limiting the statistical 
power for CD200. STAG3, a component of the meiosis 
specific cohesin complex [27] was expressed at a low level 
in B-cells, RT-qPCR of whole tumor tissue confirmed its 
differential expression between HPV(+) and HPV(−) 
tumors (Supplementary Figure S5).
IHC assessment of HPV(+) and HPV(−) tumors 
identified dense clusters of tumor-infiltrating B-cells in the 
former; Figure 7 shows representative histology for one 
HPV(+) and one HPV(−) tumor. The follicular morphology 
within HPV(+) tumors was apparent following staining for 
CD23, a marker of follicular B-cells. Furthermore, IHC 
confirmed the presence of CD200+ cells within and around 
tertiary lymphoid follicles, together with a diffuse CD8+ 
T-cell infiltrate.
Retained non-immune gene differences between 
HPV(+) and HPV(−) tumor after TIL correction
GO and pathway analysis of DEGs expressed to 
a lesser extent in HPV(+) compared to HPV(−) tumors 
were largely unchanged following TIL correction of the 
data. There were 218 lesser expressed genes following 
lymphocyte correction, of which many were associated 
with development (skin, epidermis, epithelium, tissue, 
organ) and keratinization (Supplementary Figure S2 and 
Supplementary Table S9). In addition, lesser expressed 
genes associated with IL-12 and IL-6 production, the 
inflammatory response and the response to oxidative 
stress. Individual DEG’s included keratin’s (KRT-10, 14, 
16 and 17), kallikrein-related peptidase 5, 7 and 14 (KLK5, 
7 and 14), caspase 14 (CASP14), tumor necrosis factor 
(ligand) superfamily member 9 (TNFSF9 or CD137L), 
thrombospondin receptor (CD36) and chemokine (C-C 
motif) ligand 19 (CCL19); pathway analysis of lesser 
expressed genes shown in Supplementary Table S11 
returned no significantly over-represented pathways 
(q-value <0.05).
DISCUSSION
We have previously shown that HPV(+) HNSCC 
patients with a dense immune cell infiltrate within the 
tumor have a better outcome than those with a sparse 
infiltrate [7] and show here that this is also the case 
for HPV(−) tumors. We wished to evaluate whether 
fine-resolution transcriptomic analysis could give 
insight into the biological difference in the immune 
infiltrate between patients with a known viral (HPV) 
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driver, compared with those patients where virus is 
absent. Although differential gene expression studies 
comparing HPV(+) and HPV(−) tumors have been 
reported [11, 14–17], the question as to whether the 
pathogenesis of the cancer is reflected in differences in 
immune cells themselves remains open.
In this study we focused on TILhigh/mod cases from 
our consecutive cohort and following RNA-Seq analysis 
we examined DEGs. Initially, the most striking difference 
was the immune signature, which was significantly greater 
in HPV(+) tumors and hence likely reflected an immune 
responses to viral antigens. In contrast HPV (−) tumors 
Figure 5: Expression of B-cell-associated genes by RNA-Seq. Heatmaps* to illustrate gene expression of the identified B-cell-
associated genes between HPV(+) and (−) tumors: GGA2, SPIB, CD200, STAG3, ADAM28, BCL2, VCAM1 and ICOSLG. A., a heatmap 
of our HNSCC dataset (HPV(+) n=10 and HPV(−) n=13). B., a heatmap of the TCGA HNSCC dataset (HPV(+) n=46 and HPV(−) n=26); 
publically available data from anatomically matched tumors arising in the oropharynx, tonsil and base of tongue. In both datasets, tumors 
cluster according to HPV status, with a greater expression of the identified B-cell-associated genes in HPV(+) tumors. *Unsupervised 
clustering of gene expression data was normalized using the TMM method followed by variance stabilizing transformation of the TMM 
normalized data. Each row represents normalized gene expression values for a given gene; each column represents the gene expression 
for a given tumor: red shading denotes greater gene expression, blue shading denotes lower gene expression. Hierarchical clustering of 
genes and tumors based on their expression profile is reflected in the dendrograms to the left and the top of the heatmap, respectively, and 
was performed by calculating distance using the Pearson’s correlation metric and then clustering distance using the ward linkage method.
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revealed a prominent tissue development/ re-organisation 
gene signature. The molecular data mapped well onto 
the TIL characterization afforded by IHC, although the 
variability was higher when TILs were counted manually. 
It is likely that this is a reflection of the fact that RNA-
Seq analysis uses homogenized tumor, which averages the 
geographical differences within the tissue.
A significant difference in TIL density determined 
by RNA-Seq gene transcript levels of CD4 and CD8A 
(T-cells) and CD19 (B-cells) remained between 
HPV(+) and HPV(−) patient cohorts. This was clearly 
demonstrated in the IHC assessment and by FAIME 
analysis, where in ranked order, HPV(−) TILhigh/mod patients 
had a significantly lower expression of B- and T-cell-
related genes compared with HPV(+) TILhigh/mod patients. 
In order to assess the difference between HPV(+) and 
HPV(−) TIL enriched tumors, the data were corrected 
according to the number of immune cells present in the 
tissue as determined by RNA-Seq gene transcript levels 
(CD8A, CD4 and CD19), with the aim to account for the 
numerical difference in immune cells.
RNA-Seq data that had been corrected for TIL 
number showed that the vast majority of immune-related 
DEGs were ‘lost’, suggesting that in both patient cohorts 
the lymphocytes were qualitatively similar. The T-cell 
immune signature, present in both HPV(+) and HPV(−) 
tumors, no longer showed differentially expressed genes. 
Thurlow et al. have previously demonstrated that both 
HPV(+) and HPV(−) cohorts can mount adaptive immune 
responses [19], while the association of cytolytic activity 
of effector cells and immunoediting of the tumor has also 
been reported [10]. These studies however did not correct 
for lymphocyte numbers; the HPV(+) tumors in which no 
adaptive response was detected likely represented TILlow 
patients. We had expected to find that a viral driver would 
promote a distinct T-cell-driven TIL signature, but this was 
not observed in our data. Instead, our data demonstrate that 
T-cells in TILhigh/med tumors of different pathogeneses are 
transcriptomically similar, at the level of bulk population 
analysis.
In contrast, there was a distinct B-cell signature 
between HPV(+) and HPV(−) tumors after correction 
for TIL numbers, there was a small subset of B-cell 
associated genes that continued to have greater expression 
in HPV(+) tumors, including GGA2, SPIB, CD200, 
ADAM28, BCL2, VCAM1 and ICOSLG, as determined by 
Figure 6: Relative expression of B-cell-associated genes by RT-qPCR. The average relative gene expression of B-cell-associated 
genes was measured by RT-qPCR* in HPV(+) tumors. The expression of the B-cell-associated genes GGA2, SPIB, CD200, STAG3, 
ADAM28, BCL2, VCAM1 and ICOSLG was confirmed in B-cells sorted from an independent cohort of HPV(+) tumors (n=6). *Relative 
gene expression by RT-qPCR, calculated using the comparative Ct method with Actin as the control gene (2-ΔΔCt method) (23).
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previously published datasets for B-cell gene signatures 
and the GO term (B-cell activation, GO:0042113) [21–
26]. The expression of the differentially expressed B 
cell-associated genes is not unique to B cells as they can 
be identified in other cell types. This includes CD200, 
which has been found to be expressed on 1-2% of basal 
Figure 7: Expression of B-cell markers by IHC. Cell subset anlalysis by IHC for the B-cell markers CD20, CD23 and CD200, as 
well as the T-cell marker CD8, was performed on sequential sections for HPV(+) (n=9) and HPV(−) (n=13) tumors; representative data 
is shown for one tumor from each cohort. Pseudo-follicle formation is apparent in HPV(+) tumors along with dense infiltrate of CD20+ 
B-cells. TIL density was greater in HPV(+) tumors.
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cell carcinoma cells [28]. However, our data on purified 
B-cell populations from HPV(+) HNSCC confirms the 
expression of the BCL2, ADAM28, CD200, ICOSLG and 
SPIB genes in B cells isolated from the tumors. We were 
able to confirm our DEGs in a larger, independent cohort 
derived from HNSCC TCGA data. We could show that 
the DEG are not the result of anatomical location bias 
of HPV(+) tumors, as the differences are maintained 
when anatomically matched HPV(−) and HPV(+) only 
are compared. Additionally, applying the TIL corrected 
DEG list to the TCGA confirmed the validity of our 
observations.
Greater expression of BCL2 by HNSCC has been 
proposed as a predictor of good response to chemotherapy; 
this is consistent with its expression in our HPV(+) 
cohort, a group of patients that generally respond well 
to treatment, including chemotherapy [29, 30]. During 
a normal humoral response, ICOSLG is expressed on 
activated B-cells within germnal centers, which are formed 
in follicles and are central for an antigen-specific humoral 
response. Histologically, all of our HPV(+) tumors had 
very well developed follicles/tertiary lymphoid structure 
[31]. Follicles within solid human tumors have previously 
been described in breast, cervical and non-small-cell lung 
carcinoma [32, 33]. In melanoma, ICOSLG is linked with 
increasing numbers of regulatory T-cells (Treg) [34], but 
has not previously been described in HPV(+) HNSCC. 
Interestingly, when a stimulatory ICOS antibody was 
used in combination with anti-CTLA-4, there was a 
significant improvement in tumor rejection in both 
melanoma and colon cancer mouse models, suggesting 
that HPV(+) tumors expressing high levels of ICOSLG 
may respond better to anti-CTLA-4 therapy [35]. SPIB is a 
transcriptional activator that is specific for lymphoid cells 
and has previously been identified in germinal centers 
where it was associated with an activated B-cell phenotype 
[36].
Using IHC to probe protein expression of CD200, 
we identified CD200+ B-cells within and outwith of 
follicular structures. Given that the viral antigens E6 
and E7 generate a strong B-cell response in patients with 
HPV(+) HNSCC [37], it is likely that the expression of 
the B-cell activation marker CD200 [38] is linked to a 
persistence of HPV-driven, tumor-derived antigens, which 
in turn stimulate specific B-cells in the germinal center 
and the tumor itself. It is also possible that the CD200+ 
B-cells resident at specific locations in the tumor vs. the 
follicles have a distinct phenotype and properties. These 
cells could be part of an inhibitory pathway: CD200R 
activation stimulates the differentiation of T-cells to Treg 
[39], the numerical increase of Treg in parallel with TIL 
number has been reported in HPV(+) HNSCC [40]. These 
CD200+ B cells can act through CD200R and effector 
mechanisms may include immunomodulatory cytokines, 
such as IL-10, [41] release of granzyme B [42] or other yet 
to be identified modes of action. The receptor is expressed 
on both lymphoid and myeloid cells, hence direct and 
indirect inhibition of T-cell immunity could be possible 
[43]. It must however be noted that expression of CD200 
is thought to have links to anti-tumor effects by inhibiting 
activity of tumor-associated myeloid cells via IL-10 [44], 
arguing caution in targeting a molecule with potentially 
pleiotropic effects.
It is apparent that phenotypic differences exist 
between the B-cells of HPV(+) and HPV(−) tumors. 
Data from an HPV-driven mouse tumor model supports 
a reduction in tumor growth as a result of the depletion 
of B-cells via anti-CD20 [45]. It is tempting to speculate 
that anti-CD200 could provide a more targeted approach 
to B-cell manipulation within these tumors rather than 
the use of anti-CD20, which would globally remove 
multiple B-cell subsets. In the clinic, an anti-CD200 
blocking antibody was safe and well tolerated in Phase 
II testing (NCT00648739), but as yet the clinical effects 
have not been reported. The B-cell receptor targeting 
therapies (ibrutinib) have efficacy on CD200+ cells 
within the B-CLL setting and potentially could be 
exploited [46].
This paper is the first to compare RNA-Seq data 
from HPV(+) and HPV(−) HNSCC, when controlled for 
TIL number. We have identified genes expressed both to 
a greater and lesser extent between tumor types. We are 
the first investigators to propose a correction calculation 
of transcriptomic signals in immune cells, to overcome 
the numerical imbalance between virally driven and 
virus-independent HNSCC. This analysis reveals that 
differences between the transciptome in T-cells between 
HPV(+) and HPV(−) HNSCC appears predominantly 
quantitative, but that a distinct B-cell profile exists in 
HPV(+) cancers. However, to truly assess qualitative 
differences in B- and T-cells between HPV(+) and HPV(−) 
tumors, these subsets must be isolated and analysed 
separately. Such disaggregation of tumor tissue will be the 
focus of future work.
MATERIALS AND METHODS
Study subjects and tumor processing
Following LREC approval and written informed 
consent, 39 consecutive HNSCC samples were obtained 
from patients at three centers (Southampton, n=22; 
Poole, n=15; Liverpool, n=2) from 2010-2012. Tumor 
samples were collected, following general anaesthesia 
but before surgical resection, and were snap frozen 
immediately. Cryosections (10µm) were cut and used for 
RNA isolation with the RNeasy Mini Kit (Qiagen Ltd., 
Manchester, UK). Table 1 shows the patient demographics, 
tumor characteristics and tumor sampling/processing 
information for the HPV(+) and HPV(−) patient cohorts. 
A retrospective cohort of 544 HNSCC patients were also 
used for the generation of survival data.
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Histology and immunohistochemistry
Frozen tumor sections taken immediately adjacent 
to the tissue analysed by RNA-Seq were stained with 
hematoxylin and eosin (H&E); tumors were assessed as 
TIL high (TILhigh), moderate (TILmod) and low (TILlow) by 
an accredited pathologist [G.J.T] as previously described 
[7] (Supplementary Methods S1). Formalin-fixed, 
paraffin-embedded (FFPE) tumor tissue blocks from the 
same patients were also collected and used to evaluate the 
cell surface marker expression of CD3, CD4, CD8, CD20, 
CD23 and CD200 by IHC; enumeration of CD3, CD4, 
CD8 and CD20 was expressed as an average of ten high-
power fields [7] (Supplementary Methods S1).
Survival data
Two HNSCC patient cohorts consisting of 
137 HPV(+) and 407 HPV(−) tumors were analysed 
retrospectively for survival relative to TIL density and 
HPV status. The primary endpoint was death from 
HNSCC, i.e., disease-specific survival, as previously 
described [7].
RNA-Sequencing and data analysis
RNA-Seq (Single end, 35 bp) was performed using 
the HiSeq 2000 platform (Illumina Inc., San Diego, USA) 
(Supplementary Methods S2). RNA-Seq data have been 
deposited in the Gene Expression Omnibus (GEO) at the 
National Center for Biotechnology Information (NCBI) 
under accession number GSE72536. RNA-Seq data was 
mapped using human genome (hg19) and TopHat (version 
2.0.9), counted with HTSeq-count (version 0.5.4) [47] 
and differentially expressed genes (DEGs) identified 
with EdgeR (version 3.4.2) [48, 49]. EdgeR was also 
used to identify DEGs while adjusting for the covariates 
associated with varying proportions of lymphocyte 
subsets in each tumor sample, gene expression of CD19 
(B-cells) and CD4 and CD8A (T-cells) were used as 
the covariates. Unsupervised clustering of tumors was 
performed following variance stabilizing transformation 
of trimmed mean of M-values (TMM) normalized 
data. DEGs between HPV(+) and HPV(−) tumors were 
identified with a false discovery rate (FDR) corrected 
p-value of <0.05 (i.e., q-value <0.05) and a fold change 
of >2 or <-2. A detailed description of the RNA-Seq data 
analysis performed can be found in the Supplementary 
Methods S3.
Real-time quantitative reverse transcription 
PCR
Real-time quantitative reverse transcription PCR 
(RT-qPCR) assays were performed using Taqman® probes 
for golgi-associated, gamma adaptin ear containing, ARF 
binding protein 2 (GGA2), ADAM metallopeptidase 
domain 28 (ADAM28), CD200, Spi-B transcriptional factor 
(SPIB), stromal antigen 3 (STAG3), Vascular Cell Adhesion 
Molecule 1 (VCAM1), Inducible T-Cell Co-Stimulator 
Ligand (ICOSLG) and B-Cell CLL/Lymphoma 2 (BCL2) and 
adhere to the MIQE guidelines for RT-qPCR (Supplementary 
Methods S4) [50]. Gene expression (RT-qPCR) of STAG3 and 
CD200 was validated in the original tumor RNA, HPV(+) 
n=8 and HPV(−) n=8 patient tumor samples. B-cells (CD19+) 
isolated from an independent cohort of HPV(+) tumors 
(n=6) using a BD FACSAria™ sorter (BD Biosciences, 
Oxford, UK, Supplementary Methods S4) were assessed 
for gene expression of ADAM28, BCL2, CD200, GGA2, 
ICOSLG, SPIB, STAG3, and VCAM1. RT-qPCR analysis 
was performed using the comparative Ct (cycle threshold) 
method (2-ΔΔCt) using Actin as the control gene and is defined 
as a normalized relative gene expression compared to a the 
control gene [51].
Gene ontology and pathway analysis
GO terms associated with biological processes 
and biological pathways that were significantly over-
represented for DEGs (q-value <0.05) were identified 
with ConsensusPathDB [20] (CPDB, release 30) using the 
hypergeometric test. ConsensusPathDB represents a first 
generation tool for functional genomics and was sufficient 
for the purpose of showing the change in GO terms and 
pathways before and after correction for the number of 
B- and T-cells between HPV(+) and HPV(−) tumors. GO 
and pathway analyses were performed for genes that were 
expressed (i) to a greater extent and (ii) to a lesser extent 
in HPV(+) compared to HPV(−) tumors.
Molecular quantification of TILs in HPV(+) and 
HPV(−) tumors
The distribution and proportions of TILs were 
assessed at both the tumor sample and group level. At 
the sample level, the gene expression (RNA-Seq) and 
surface protein expression (IHC) of CD3, CD20, CD4 and 
CD8 were evaluated. In addition, “Functional Analysis of 
Individual RNA-Seq or Microarray Expression” (FAIME) 
[52] was adapted to generate a score for a large number 
of tissues and cell types, including B-cells and CD4+ 
and CD8+ T-cells (additional details in Supplementary 
Methods S5 and Supplementary Table S6). The FAIME 
score was calculated for each cell type, for each tumor 
and was followed by a student’s t-test to assess whether 
the FAIME scores for a particular cell subset were 
significantly different (q-value <0.05) between the HPV(+) 
and HPV(−) cohorts.
Validation of findings in TCGA data set
HNSCC RNA-Seq data (TCGA HNSC HiSeqV2 
2015-02-24) was obtained from The Cancer Genome 




Seq methodology and processing have been described 
by TCGA [11]. As HPV-driven cancers typically arise in 
the oropharynx, tonsil and base of tongue, we identified 
and evaluated tumors matched for these anatomical sites 
from TCGA. Unsupervised clustering of 46 HPV16(+) 
and 26 HPV(−) anatomically matched tumors from the 
oropharynx, tonsil and base of tongue was performed 
using the differential gene lists generated from our own 
analysis.
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